Fate Therapeutics, Inc. FATE
2.07 USD +0.03 (+1.62%)
Nov 4, 2026, 3:39 PM EST
2.03 Day range 2.10
0.95 52-week range 3.23
- YTD
- +111.53%
- 1 year
- +74.20%
- Market cap
- 248.03M
- Revenue (ttm)
- 13.45M
- EPS (ttm)
- -1.05
- Shares out
- 113.89M
- Forward P/E
- -0.99
- YTD return
- +111.53%
- 1-year return
- +74.20%
- Volume
- 520.79K
- Avg volume
- 1.49M
- Open
- 2.05
- Previous close
- 2.04
- Day's range
- 2.03 – 2.10
- 52-week range
- 0.95 – 3.23
- Beta
- 1.88
- Analysts
- Buy
- Price target
- 6.31 (+204.3%)
2Y -0.69 (-25.00%)
Key statistics
- Enterprise value
- -6.60M
- PEG ratio
- 0.00
- Price / sales
- 14.06
- Price / book
- 0.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 58.10%
- Free cash flow
- -58.50M
- Total cash
- 296.92M
- Total debt
- 98.98M
- Return on equity
- -46.59%
- Short % of float
- 11.43%
- 50-day average
- 2.53
- 200-day average
- 3.93
Analyst view
Consensus: buy
Buy
Price target (mean) 6.31 +204.3% upside
Now 2.07
- Target (low)
- 3.00
- Target (mean)
- 6.31
- Target (high)
- 10.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
- Strong buy2
- Buy4
- Hold12
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.43055.
Financials — quick view
FATE Revenue — quarterly 2.08M
FATE Net income — quarterly -30.16M
FATE EPS — quarterly -0.25
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.42 | -0.40 | +0.02 | +4.76% |
| Aug 13, 2024 | Jun 1, 2024 | -0.47 | -0.33 | +0.14 | +29.79% |
| May 9, 2024 | Mar 1, 2024 | -0.47 | -0.47 | 0.00 | 0.00% |
| Feb 26, 2024 | Dec 1, 2023 | -0.57 | -0.45 | +0.12 | +21.05% |
| Nov 8, 2023 | Sep 1, 2023 | -0.59 | -0.46 | +0.13 | +22.03% |
| Aug 8, 2023 | Jun 1, 2023 | -0.58 | -0.54 | +0.04 | +6.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Needham | reit | — | Hold |
| Nov 13, 2024 | Needham | reit | — | Hold |
| Aug 22, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 14, 2024 | Needham | reit | — | Hold |
| Jun 17, 2024 | Piper Sandler | up | Neutral | Overweight |
| May 16, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fatetherapeutics.com
News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) 
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target 
Fate Therapeutics Presents Updated Phase 1 Clinical Data For FT819, Off-The-Shelf, Available On-Demand, Anti-CD19 CAR T-Cell Product Candidate, In Patients With SLE With Lupus Nephritis At ASN Kidney Week 2026 
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) 
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences 
CIRM backs Fate’s FT819 lupus trial - Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN 
Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026
Your note
Sign in to keep a note on FATE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHU YU-WAYE | Officer | Sale | Apr 17, 2023 | 140,676 |
| DULAC EDWARD J III | Chief Financial Officer | Sale | Mar 3, 2024 | 101,479 |
| MENDLEIN JOHN D | Director | Conversion of Exercise of derivative security | Jan 18, 2023 | 311,231 |
| PLAVSIC MARK | Chief Technology Officer | Sale | Jan 9, 2023 | 123,705 |
| POWL BRIAN T | Officer | Sale | Jul 4, 2023 | 41,146 |
| REDMILE GROUP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Dec 11, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Redmile Group, LLC | 11.56% | 13,169,057 | 21.86M | Sep 29, 2024 |
| Blackrock Inc. | 9.20% | 10,473,250 | 17.39M | Sep 29, 2024 |
| Vanguard Group Inc | 9.13% | 10,404,123 | 17.27M | Sep 29, 2024 |
| Deep Track Capital, Lp | 4.89% | 5,572,607 | 9.25M | Sep 29, 2024 |
| State Street Corporation | 4.61% | 5,252,974 | 8.72M | Sep 29, 2024 |
| Boxer Capital, LLC | 4.36% | 4,960,910 | 8.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.68% | 3,049,285 | 5.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.27% | 2,582,631 | 4.29M | Oct 30, 2024 |
| Vanguard Strategic Equity Fund | 2.23% | 2,540,354 | 4.22M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.16% | 2,464,707 | 4.09M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.24% | 1,409,518 | 2.34M | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 1.11% | 1,268,133 | 2.11M | Jul 30, 2024 |